Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 18, 2012

FDA Okays Meridian’s Strep Throat Diagnostic

  • FDA cleared Meridian Bioscience’s illumingene® molecular diagnostic test for Group A Streptococcus pharyngitis. The test, carried out on the illumigene molecular diagnostic platform, uses loop-mediated isothermal DNA amplification to detect Streptococcus pyogenes in throat samples, takes less than an hour to complete, and the kit includes all reagents and disposables that can be stored at room temperature.

    “Our diagnostic tests are specifically developed for faster and more accurate detection and early diagnosis of acute infectious disease-causing pathogens,” states Jack Kraeutler, CEO. “With illumigene Group A Strep, healthcare providers and patients can get a definitive strep throat diagnosis rapidly.”

    Meridian offers a broad range of diagnostic test kits, purified reagents and biopharmaceutical enabling technologies. The firm’s diagnostic portfolio includes tests for the early diagnosis of Clostridium difficile, Helicobacter pylori, foodborne diseases, and respiratory infections. 



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »